By Lilian Massihi, MD, Board-Certified Family Medicine, Advanced BHRT Certification
You did not come in about your bones. You came in about the sleep, or the hot flashes, or the weight that moved to your middle and will not move back. Bones never came up. There was nothing to bring up. Nothing aches, nothing clicks, nothing has broken.
Or you did ask. You said you were in your late forties and had read something about bone density, and you were told you were too young, that bone scans start at sixty five, and to raise it again then.
Both of those visits are missing the same thing. The years when a woman loses bone fastest are the years right around her last period, and there is no symptom to report while it happens. By the time there is something to feel, the part you could have measured is already behind you.
This is the one change of the menopause transition that is completely silent and almost completely measurable. Those two facts together are the whole argument of this article.
Why nothing hurts, and why that is not reassuring
Bone loss does not announce itself. The National Institute of Arthritis and Musculoskeletal and Skin Diseases, the arm of the National Institutes of Health responsible for bone disease, calls osteoporosis a silent disease for exactly this reason: there are typically no symptoms at all until a bone breaks. The breaks, when they come, happen most often in the hip, the vertebrae of the spine and the wrist.
So the absence of symptoms is not a result. It is the absence of a test. That distinction matters more here than almost anywhere else in menopause care, because every other change in the transition does eventually knock on the door. This one does not.
The same institute notes something that rarely gets said out loud in a seven minute appointment: for many women, the disease begins to develop a year or two before menopause. Not after. Before.
The window has a name, and it is narrower than you would guess
The best picture of the timing comes from the Study of Women’s Health Across the Nation, a long-running observational study that followed women through the transition rather than catching them after it. In its analysis of bone density around the final menstrual period, published in the Journal of Bone and Mineral Research, the official journal of the American Society for Bone and Mineral Research, researchers tracked 862 women who were premenopausal or early perimenopausal when they enrolled and who later reached their final period.
Bone loss began one year before that final period and slowed, without stopping, two years after it. The researchers named that roughly three year stretch the transmenopause, and the numbers inside it are the reason to care about the dates.
Across the full ten years they measured, the lumbar spine lost 10.6 percent of its density. Of that, 7.38 percent was lost during the transmenopause alone. At the femoral neck, the part of the hip that actually breaks, the ten year loss was 9.1 percent, with 5.8 percent of it in the same short window.
Read those two pairs of numbers again. Roughly seven tenths of a decade of spine loss, and nearly two thirds of a decade of hip loss, happen inside about three years.
Here is the cruel part of the arithmetic. A final period can only be identified in hindsight, after twelve months have passed with no bleeding. So by the time any woman can say with certainty that she is postmenopausal, she is already standing at the far end of the fastest loss of her life. Waiting for certainty guarantees you miss it.
Why estrogen is the lever here
Bone is not scaffolding. It is living tissue that is taken apart and rebuilt continuously, and the two halves of that process are supposed to stay in balance. Estrogen restrains the taking apart. When estradiol falls, the breakdown side runs ahead of the rebuilding side, and the balance tips toward net loss.
The Endocrine Society, the professional body for hormone specialists, puts it plainly: menopause is the most common cause of osteoporosis, up to 20 percent of bone loss can occur during the menopausal and postmenopausal stages, and one in two postmenopausal women will have osteoporosis.
One in two. Not a rare outcome in an unlucky minority. The statistical expectation for half the women reading this.
That is also why bone and muscle move together through this transition rather than separately. The same drop that accelerates bone breakdown is at work in the muscle you have been losing, and the two tissues share more than a cause. Muscle is what loads bone.
The screening gap, stated fairly
Routine bone density screening in the United States is keyed to age, not to the transition. As the NIH’s summary of the U.S. Preventive Services Task Force recommendation states, screening is recommended for women over age 65, and for women of any age who have factors that raise their chance of developing osteoporosis.
That is a reasonable population rule and it is not a scandal. Screening recommendations are written to decide where a national health system should spend a test, and by that measure age 65 is a defensible line.
But notice what the rule does to the individual woman. She is 51, inside the window the SWAN data identified, losing bone faster than she will at any later point, with no symptom that would qualify her as higher risk. The rule, working exactly as designed, will not measure her for another fourteen years.
The second clause is the one worth knowing by heart, because it is the one that applies to real people: women of any age with risk factors. Early menopause, a parent who fractured a hip, a prior fracture of your own after a minor fall, long courses of steroids, an overactive thyroid, smoking, a very low body weight, significant alcohol use. Those are not footnotes. They are the door.
What is actually measurable right now
This is the part that makes the silence survivable. You cannot feel bone loss, but very little of it is hidden from a lab or a scanner.
- Bone mineral density by DXA. Dual energy x-ray absorptiometry, the standard measurement, is quick, painless and noninvasive, and it returns a T-score comparing your density against a young adult reference. One scan is a snapshot. Two scans, a few years apart, are a trajectory, which is the far more useful object.
- Bone turnover markers. These are blood or urine tests that read the rate of bone breakdown and bone formation, rather than the amount of bone present. A density scan tells you where you are. Turnover tells you which direction you are moving, and it moves months before a scan does.
- Vitamin D and calcium status. Calcium is the raw material and vitamin D is what lets the body absorb it. The Endocrine Society is direct about the dependency: without enough vitamin D, your body will not absorb the calcium in your diet, however much of it you eat.
- The conditions that quietly accelerate loss. Thyroid function sits at the top of that list. A thyroid running too fast speeds bone turnover, and it is a blood test, not a guess.
Which of these belongs in your workup depends on your history, your age and your risk factors, and that is a physician’s call made with your chart open, not a checklist to be applied to everyone identically.
What the research says about hormones and fracture
The largest randomized evidence on hormone therapy and broken bones comes from the trial most women have heard of for the opposite reason. The Women’s Health Initiative randomized 16,608 postmenopausal women aged 50 to 79 to hormone therapy or placebo and followed them for an average of 5.6 years. Its fracture analysis, published in JAMA, the peer-reviewed journal of the American Medical Association, reported fractures in 8.6 percent of the treated group against 11.1 percent on placebo, a hazard ratio of 0.76 with a 95 percent confidence interval of 0.69 to 0.83. Bone density at the total hip rose 3.7 percent over three years compared with placebo.
Two things have to be said about that trial in the same breath, and most coverage says only one of them.
The first is that this is a genuine randomized finding on fractures, not an association teased out of a database afterward. The second is that the trial used conjugated equine estrogen combined with medroxyprogesterone acetate. Those are synthetic hormones, not the bioidentical estradiol and micronized progesterone used in modern hormone optimization, and the average woman enrolled was well past her own transition rather than inside it. That design is the reason the trial’s harms were overstated for a generation, and the same design qualifies its benefits. We have written about what the WHI actually showed and what it did not at length.
So the honest statement is this. Estrogen’s effect on the bone remodeling balance is not in dispute, and the largest fracture trial ever run points the same direction as the mechanism. Whether hormone therapy is an appropriate part of your own plan is a separate question that depends on your history, your risk review and your goals, and it is answered in a consultation rather than in an article.
The part that is not hormonal, and it is not walking
Bone responds to load, and it responds to the size and the speed of the load rather than to the hours spent. That is why walking, which is worth doing for a dozen other reasons, is a weak signal to bone.
The clearest trial on this enrolled 101 postmenopausal women, average age 65, all with low bone mass. For eight months, half did two supervised 30 minute sessions a week of heavy resistance and impact work. The other half did a low intensity program at home. The results, published in the Journal of Bone and Mineral Research, favored the heavy group at every bone and function measure: lumbar spine density rose 2.9 percent in the trained group while falling 1.2 percent in the home group, and femoral neck density rose 0.3 percent against a 1.9 percent fall.
Sixty minutes a week. Density rising in women whose bone was already thin.
The obvious fear about that approach was addressed directly. A follow-up analysis of the same participants looked for spinal fractures and found none, and measures of thoracic kyphosis, the forward curve of the upper back, actually improved.
Two caveats that the trial itself insists on. Every session was supervised by someone trained to coach the lifts, and every participant was screened first for conditions and medications that affect bone. This is a reason to get properly assessed and properly coached, not a reason to load a barbell on Monday on the strength of a blog post.
What to do with this
If you take one thing from this article, let it be the reframe rather than any single number. Every other symptom of this transition tells you it is there. This one will not, and the window where it matters most is already open or about to be.
That makes bone an argument for measuring rather than waiting. Not because measurement is reassuring, it often is not, but because a trajectory caught at 51 leaves room for decisions that a fracture at 68 does not. If you want to see what a full evaluation actually looks at, including the bone and thyroid work that rarely appears in a standard panel, start with what we test.
Frequently Asked Questions
Will I feel it if I am losing bone?
No. That is the defining feature of the disease rather than an unlucky variation. The NIH describes osteoporosis as silent precisely because there are typically no symptoms until a bone breaks. Back pain, a loss of height or a stooped posture can appear once a vertebra has already fractured, which is late.
I am 48. Can I even get a bone density scan?
Yes. The age 65 figure is the threshold for routine population screening, not a rule about who is permitted to be scanned. The same recommendation explicitly covers women of any age who carry factors that raise their risk, and your menstrual history is part of that picture. Bring the question to a physician with your history in front of her rather than deciding on your own that you are too young to ask.
Does hormone therapy rebuild bone or only slow the loss?
In the Women’s Health Initiative, total hip bone density rose 3.7 percent over three years against placebo, so the measured change was upward rather than merely flat. That is a trial average in a group given synthetic hormones, however, and it is not a prediction about any individual. The useful framing is that estrogen acts on the breakdown side of bone remodeling, and what that produces in you depends on where you are starting, how long you have been without it, and what else is going on.
I went through menopause early. Does that change the picture?
It is one of the risk factors that moves you out of the age based screening rule and into the risk based one, because an earlier final period means more years spent without estrogen’s restraint on bone breakdown. If your periods stopped well before the average, say so in the first five minutes of your appointment and ask what should be measured now.
Are calcium and vitamin D enough on their own?
They are the foundation and they are not the whole structure. Calcium is the raw material, vitamin D is what allows it to be absorbed, and a deficit in either one limits everything else you do. Neither of them replaces the load signal that resistance work supplies, and neither addresses the hormonal shift that opened the gap in the first place.
What if a scan comes back showing osteopenia?
Osteopenia is lower than young adult density without meeting the threshold for osteoporosis, and it is information rather than a verdict. It is also the stage where the range of reasonable options is widest, which is the argument for finding out early rather than late.
AllureMD is a physician-led hormone optimization practice in Madison, Mississippi. Bone is the clearest case for measuring instead of waiting, because it is the one change of this transition that will never tell you it is happening. Lilian Massihi, MD evaluates each patient’s complete hormonal picture before making any recommendation. To schedule your consultation, book a complimentary discovery call.
About the Author
Lilian Massihi, MD is a board-certified family medicine physician and hormone optimization specialist who completed her undergraduate education at UCLA, earned her medical degree at the University of Poznań, and finished her residency at the University of Mississippi Medical Center. For more than five years, she practiced as a hospitalist, treating patients in the late stages of cardiovascular disease, cognitive decline, and severe osteoporosis. She kept asking the same question: what would have been different if someone had intervened sooner? That question led her to bioidentical hormone therapy, where a rigorous review of the evidence changed the direction of her career. She founded AllureMD in Madison, Mississippi to practice the kind of medicine she had come to believe in: treating the entire hormonal system, titrating to how patients actually feel, with a physician leading every decision.